TREATMENT OF CHRONIC HEPATITIS C: PEG-INTRON AND RIBAVIRIN WITH OR WITHOUT KATT

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。这是一项针对丙型肝炎患者的研究，以前从未接受过治疗。现有数据表明，在治疗过程中保持全剂量的药物对于能够取得成功的结果至关重要。低血细胞计数占药物剂量减少的三分之一以上。我们正试图表明，更多的患者将通过使用其他药物来帮助支持血细胞计数，并通过使用更积极的截止点来减少或停止药物来清除丙型肝炎病毒。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a study for patients who have hepatitis C and have never been treated before. Available data suggest that maintaining full dose of medication during the course of the treatment is crucial in being able to achieve a successful outcome. Low blood cell counts account for over one-third of these reductions in medication dosage. We are trying to show that more patients will clear the hepatitis C virus by using other medications to help support the blood cell counts and by using more aggressive cut-off points for reducing or stopping the medications.